These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 36933003)
1. Markers of placental function correlate with prevalence and quantity of nucleated fetal cells in maternal circulation in normotensive term pregnancies. Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC Acta Obstet Gynecol Scand; 2023 Jun; 102(6):690-698. PubMed ID: 36933003 [TBL] [Abstract][Full Text] [Related]
2. Fetal-origin cells in maternal circulation correlate with placental dysfunction, fetal sex, and severe hypertension during pregnancy. Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC J Reprod Immunol; 2024 Mar; 162():104206. PubMed ID: 38309014 [TBL] [Abstract][Full Text] [Related]
3. Poor glucose control and markers of placental dysfunction correlate with increased circulating fetal microchimerism in diabetic pregnancies. Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC J Reprod Immunol; 2023 Sep; 159():104114. PubMed ID: 37473584 [TBL] [Abstract][Full Text] [Related]
4. Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: A prospective observational study. Mitlid-Mork B; Bowe S; Gran JM; Bolstad N; Berg JP; Redman CW; Staff AC; Sugulle M PLoS One; 2020; 15(10):e0240473. PubMed ID: 33079955 [TBL] [Abstract][Full Text] [Related]
5. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia. Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800 [TBL] [Abstract][Full Text] [Related]
6. The association between placenta-associated circulating biomarkers and composite adverse delivery outcome of a likely placental cause in healthy post-date pregnancies. Bowe S; Mitlid-Mork B; Georgieva A; Gran JM; Redman CWG; Staff AC; Sugulle M Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1893-1901. PubMed ID: 34212381 [TBL] [Abstract][Full Text] [Related]
7. Alterations in maternal sFlt-1 and PlGF: Time to labor onset in term-/late-term pregnancies with and without placental dysfunction. Mitlid-Mork B; Bowe S; Staff AC; Sugulle M Pregnancy Hypertens; 2022 Dec; 30():148-153. PubMed ID: 36228400 [TBL] [Abstract][Full Text] [Related]
8. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia. Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758 [TBL] [Abstract][Full Text] [Related]
9. Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage. Jayasena CN; Abbara A; Comninos AN; Narayanaswamy S; Gonzalez Maffe J; Izzi-Engbeaya C; Oldham J; Lee TT; Sarang Z; Malik Z; Dhanjal MK; Williamson C; Regan L; Bloom SR; Dhillo WS Hum Reprod; 2016 Dec; 31(12):2681-2688. PubMed ID: 27664209 [TBL] [Abstract][Full Text] [Related]
10. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study. Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323 [TBL] [Abstract][Full Text] [Related]
11. Angiogenic imbalance in pre-eclampsia and fetal growth restriction: enhanced soluble fms-like tyrosine kinase-1 binding or diminished production of placental growth factor? Kluivers ACM; Biesbroek A; Visser W; Saleh L; Russcher H; Danser AHJ; Neuman RI Ultrasound Obstet Gynecol; 2023 Apr; 61(4):466-473. PubMed ID: 36191149 [TBL] [Abstract][Full Text] [Related]
12. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Zeisler H; Llurba E; Chantraine FJ; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Schoedl M; Grill S; Hund M; Verlohren S Ultrasound Obstet Gynecol; 2019 Mar; 53(3):367-375. PubMed ID: 30014562 [TBL] [Abstract][Full Text] [Related]
13. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age. Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218 [TBL] [Abstract][Full Text] [Related]
14. Toward a new taxonomy of obstetrical disease: improved performance of maternal blood biomarkers for the great obstetrical syndromes when classified according to placental pathology. Romero R; Jung E; Chaiworapongsa T; Erez O; Gudicha DW; Kim YM; Kim JS; Kim B; Kusanovic JP; Gotsch F; Taran AB; Yoon BH; Hassan SS; Hsu CD; Chaemsaithong P; Gomez-Lopez N; Yeo L; Kim CJ; Tarca AL Am J Obstet Gynecol; 2022 Oct; 227(4):615.e1-615.e25. PubMed ID: 36180175 [TBL] [Abstract][Full Text] [Related]
15. Similar Pro- and Antiangiogenic Profiles Close to Delivery in Different Clinical Presentations of Two Pregnancy Syndromes: Preeclampsia and Fetal Growth Restriction. Dymara-Konopka W; Laskowska M; Grywalska E; Hymos A; Błażewicz A; Leszczyńska-Gorzelak B Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674486 [TBL] [Abstract][Full Text] [Related]
16. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia. Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831 [TBL] [Abstract][Full Text] [Related]
17. Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy. Park HJ; Kim SH; Jung YW; Shim SS; Kim JY; Cho YK; Farina A; Zanello M; Lee KJ; Cha DH BMC Pregnancy Childbirth; 2014 Jan; 14():35. PubMed ID: 24444293 [TBL] [Abstract][Full Text] [Related]
18. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study. MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567 [TBL] [Abstract][Full Text] [Related]
19. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. Aggarwal PK; Chandel N; Jain V; Jha V J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568 [TBL] [Abstract][Full Text] [Related]
20. Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks' pregnancy in normotensive women. Wataganara T; Pratumvinit B; Lahfahroengron P; Pooliam J; Talungchit P; Leetheeragul J; Sukpanichnant S J Perinat Med; 2017 Oct; 45(7):895-901. PubMed ID: 28665791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]